Browse Studies — Arctuva

Phase 1

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, hea…

Sinonasal Neuroendocrine CarcinomaNasopharyngeal CarcinomaEsthesioneuroblastoma+7 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06479811

Phase 1

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24…

MelanomaMedullary Thyroid CancerSinonasal Undifferentiated Carcinoma+8 more

Estimated

~$10 – $6,250

University of ArizonaNCT06814496

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

Background: Olfactory neuroblastoma (ONB) is a rare cancer. It grows from tissue in the upper part of the nose cavity, related to the sense of smell and can a…

Olfactory NeuroblastomaEsthesioneuroblastoma

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT04755205

Phase 4

68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.

The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and incl…

CNS TumorsMeningiomaEsthesioneuroblastoma+4 more

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT04081701